Literature DB >> 30442715

The potential impact of azithromycin in idiopathic pulmonary fibrosis.

Claudio Macaluso1,2, Joaquín Maritano Furcada1,2, Omamah Alzaher1, Ritesh Chaube1, Felix Chua1, Athol U Wells1, Toby M Maher1,3, Peter M George1, Elizabeth A Renzoni1, Philip L Molyneaux1,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30442715     DOI： 10.1183/13993003.00628-2018

Source DB:  PubMed          Journal:  Eur Respir J        ISSN： 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  12 in total

1.  Radiographic Honeycombing and Altered Lung Microbiota in Patients with Idiopathic Pulmonary Fibrosis.

Authors:  Robert P Dickson; Gary B Huffnagle; Kevin R Flaherty; Eric S White; Fernando J Martinez; John R Erb-Downward; Bethany B Moore; David N O'Dwyer
Journal:  Am J Respir Crit Care Med       Date:  2019-12-15       Impact factor: 21.405

Review 2.  The impact of lung microbiota dysbiosis on inflammation.

Authors:  Daping Yang; Yingying Xing; Xinyang Song; Youcun Qian
Journal:  Immunology       Date:  2019-11-11       Impact factor: 7.397

Review 3.  The evolving role of the lung microbiome in pulmonary fibrosis.

Authors:  Jay H Lipinski; Bethany B Moore; David N O'Dwyer
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2020-09-02       Impact factor: 5.464

4.  Lung microbiota predict chronic rejection in healthy lung transplant recipients: a prospective cohort study.

Authors:  Michael P Combs; David S Wheeler; Jenna E Luth; Nicole R Falkowski; Natalie M Walker; John R Erb-Downward; Vibha N Lama; Robert P Dickson
Journal:  Lancet Respir Med       Date:  2021-01-15       Impact factor: 30.700

Review 5.  The oncogenic landscape of the idiopathic pulmonary fibrosis: a narrative review.

Authors:  Giulia Maria Stella; Vito D'Agnano; Davide Piloni; Laura Saracino; Sara Lettieri; Francesca Mariani; Andrea Lancia; Chandra Bortolotto; Pietro Rinaldi; Francesco Falanga; Cristiano Primiceri; Angelo Guido Corsico; Andrea Bianco
Journal:  Transl Lung Cancer Res       Date:  2022-03

Review 6.  Management of Fibrosing Interstitial Lung Diseases.

Authors:  Toby M Maher; Wim Wuyts
Journal:  Adv Ther       Date:  2019-05-22       Impact factor: 3.845

7.  Bacterial burden in the lower airways predicts disease progression in idiopathic pulmonary fibrosis and is independent of radiological disease extent.

Authors:  Rachele Invernizzi; Joseph Barnett; Bhavin Rawal; Arjun Nair; Poonam Ghai; Shaun Kingston; Felix Chua; Zhe Wu; Athol U Wells; Elizabeth R Renzoni; Andrew G Nicholson; Alexandra Rice; Clare M Lloyd; Adam J Byrne; Toby M Maher; Anand Devaraj; Philip L Molyneaux
Journal:  Eur Respir J       Date:  2020-04-03       Impact factor: 16.671

Review 8.  The Role of the Lung's Microbiome in the Pathogenesis and Progression of Idiopathic Pulmonary Fibrosis.

Authors:  Paolo Spagnolo; Philip L Molyneaux; Nicol Bernardinello; Elisabetta Cocconcelli; Davide Biondini; Federico Fracasso; Mariaenrica Tiné; Marina Saetta; Toby M Maher; Elisabetta Balestro
Journal:  Int J Mol Sci       Date:  2019-11-10       Impact factor: 5.923

Review 9.  Much More Than IL-17A: Cytokines of the IL-17 Family Between Microbiota and Cancer.

Authors:  Arianna Brevi; Laura Lucia Cogrossi; Giulia Grazia; Desirée Masciovecchio; Daniela Impellizzieri; Lucrezia Lacanfora; Matteo Grioni; Matteo Bellone
Journal:  Front Immunol       Date:  2020-11-10       Impact factor: 7.561

10.  Deglycosylated Azithromycin Attenuates Bleomycin-Induced Pulmonary Fibrosis via the TGF-β1 Signaling Pathway.

Authors:  Hao Ruan; Shaoyan Gao; Shuangling Li; Jiaoyan Luan; Qiuyan Jiang; Xiaohe Li; Huijun Yin; Honggang Zhou; Cheng Yang
Journal:  Molecules       Date:  2021-05-10       Impact factor: 4.411
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.